

Naoto T Ueno

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2474462/naoto-t-ueno-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

330
papers

13,492
citations

56
h-index

106
g-index

355
ext. papers

15,883
ext. citations

6.5
avg, IF

6.01
L-index

#	Paper	IF	Citations
330	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. <i>Npj Breast Cancer</i> , 2022 , 8, 12	7.8	0
329	A gene signature consisting of ubiquitin ligases and deubiquitinating enzymes of SKP2 is associated with clinical outcome in breast cancer.. <i>Scientific Reports</i> , 2022 , 12, 2478	4.9	
328	Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy.. <i>JCO Precision Oncology</i> , 2022 , 6, e2000368	3.6	1
327	Ensemble of nucleic acid absolute quantitation modules for copy number variation detection and RNA profiling.. <i>Nature Communications</i> , 2022 , 13, 1791	17.4	1
326	A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer. <i>Scientific Reports</i> , 2021 , 11, 22242	4.9	3
325	Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review. <i>PLoS ONE</i> , 2021 , 16, e0250057	3.7	1
324	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. <i>Genome Medicine</i> , 2021 , 13, 70	14.4	2
323	PI3K and MAPK Pathways as Targets for Combination with the Pan-HER Irreversible Inhibitor Neratinib in HER2-Positive Breast Cancer and TNBC by Kinome RNAi Screening. <i>Biomedicines</i> , 2021 , 9,	4.8	2
322	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 455-461	4.4	1
321	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. <i>Nature Communications</i> , 2021 , 12, 3528	17.4	18
320	Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 8610-8621	3.1	2
319	Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression. <i>Breast Cancer Research and Treatment</i> , 2021 , 189, 333-345	4.4	0
318	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
317	Inflammatory Breast Cancer at the Extremes of Age. <i>Annals of Surgical Oncology</i> , 2021 , 28, 5626-5634	3.1	1
316	Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy. <i>Seminars in Ultrasound, CT and MRI</i> , 2021 , 42, 164-183	1.7	
315	Update on systemic treatment for newly diagnosed inflammatory breast cancer. <i>Journal of Advanced Research</i> , 2021 , 29, 1-12	13	3
314	Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 296-306	6.1	5

313	Body composition and breast cancer risk and treatment: mechanisms and impact. <i>Breast Cancer Research and Treatment</i> , 2021 , 186, 273-283	4.4	10
312	Decorin-mediated suppression of tumorigenesis, invasion, and metastasis in inflammatory breast cancer. <i>Communications Biology</i> , 2021 , 4, 72	6.7	10
311	Optimal Supportive Care for Patients With Metastatic Breast Cancer According to Their Disease Progression Phase. <i>JCO Oncology Practice</i> , 2021 , 17, 177-183	2.3	2
310	The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021 , 28, 4265-4274	3.1	5
309	Chemical generation of small molecule-based bispecific antibody-drug conjugates for broadening the target scope. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 32, 116013	3.4	2
308	Inflammatory breast cancer appearance at presentation is associated with overall survival. <i>Cancer Medicine</i> , 2021 , 10, 6261-6272	4.8	2
307	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
306	Lipocalin 2 promotes inflammatory breast cancer tumorigenesis and skin invasion. <i>Molecular Oncology</i> , 2021 , 15, 2752-2765	7.9	3
305	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , 2021 , 13,	6.6	2
304	Estrogen Receptor β Mediated Inhibition of Actin-Based Cell Migration Suppresses Metastasis of Inflammatory Breast Cancer. <i>Cancer Research</i> , 2021 , 81, 2399-2414	10.1	1
303	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Onc Immunology</i> , 2021 , 10, 1929724	7.2	4
302	Advances in Oncology in US and Japan: Focusing on Cancer and Infectious Diseases.. <i>World Journal of Oncology</i> , 2021 , 12, 183-194	16.7	
301	NDRG1 in Aggressive Breast Cancer Progression and Brain Metastasis. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	2
300	Quantified Kinematics to Evaluate Patient Chemotherapy Risks in Clinic. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 583-601	5.2	1
299	Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. <i>BMC Cancer</i> , 2020 , 20, 430	4.8	3
298	The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. <i>Journal of Pathology</i> , 2020 , 251, 63-73	9.4	4
297	Non-Phosphorylatable PEA-15 Sensitises SKOV-3 Ovarian Cancer Cells to Cisplatin. <i>Cells</i> , 2020 , 9,	7.9	4
296	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. <i>Oncologist</i> , 2020 , 25, e909-e919	5.7	1

295	Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. <i>Cancer Research</i> , 2020 , 80, 1304-1315	10.1	16
294	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. <i>PLoS ONE</i> , 2020 , 15, e0231953	3.7	6
293	JNK Signaling in Stem Cell Self-Renewal and Differentiation. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	23
292	EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream [®] in patients with breast cancer treated with primary systemic therapy. <i>PLoS ONE</i> , 2020 , 15, e0229903	3.7	11
291	Abstract P3-01-10: NdrG1-egfr axis in inflammatory breast cancer tumorigenesis and brain metastasis 2020 ,		2
290	Inflammatory breast cancer cells are characterized by abrogated TGF β -dependent cell motility and SMAD3 activity. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 385-395	4.4	11
289	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. <i>Scientific Reports</i> , 2020 , 10, 8537	4.9	13
288	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 1025-1032	4.8	11
287	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020 , 14, 504-519	7.9	13
286	Ablation of Stromal Cells with a Targeted Proapoptotic Peptide Suppresses Cancer Chemotherapy Resistance and Metastasis. <i>Molecular Therapy - Oncolytics</i> , 2020 , 18, 579-586	6.4	4
285	The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 729-739	4.4	0
284	Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4603-4612	3.1	5
283	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , 2020 , 4, 839-853	5.2	6
282	Targeting Signaling Pathways in Inflammatory Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	8
281	NDRG1 Expression Is an Independent Prognostic Factor in Inflammatory Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
280	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 1588-1595	3.6	8
279	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		
278	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		

277	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		
276	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		
275	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		
274	Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research 2020 , 15, e0231953		
273	Patient reported outcomes can improve performance status assessment: a pilot study. <i>Journal of Patient-Reported Outcomes</i> , 2019 , 3, 41	2.6	17
272	Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. <i>PLoS ONE</i> , 2019 , 14, e0222336	3.7	11
271	Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach. <i>Practical Radiation Oncology</i> , 2019 , 9, 402-409	2.8	2
270	The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. <i>Journal of Cancer</i> , 2019 , 10, 2635-2642	4.5	2
269	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019 , 120, 1105-1112	8.7	15
268	Elevated serum levels of sialyl Lewis X (sLe) and inflammatory mediators in patients with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 545-556	4.4	10
267	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 1025-1035	12.5	42
266	Imaging features of triple-negative breast cancers according to androgen receptor status. <i>European Journal of Radiology</i> , 2019 , 114, 167-174	4.7	7
265	Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 175, 339-351	4.4	10
264	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019 , 11, 1758835919866065	5.4	17
263	Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium. <i>Journal of Cancer</i> , 2019 , 10, 3344-3351	4.5	10
262	Bone Metastasis of Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1152, 105-129	3.6	23
261	Cooperative Effect of Oncogenic and in an HGF-Dominant Environment in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2019 , 18, 399-412	6.1	5
260	Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model. <i>Oncologist</i> , 2019 , 24, 1322-1330	5.7	3

259	Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. <i>Oncogene</i> , 2019 , 38, 2135-2150	9.2	15
258	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019 , 37, 345-351	4.3	20
257	Factors associated with improved outcomes for metastatic inflammatory breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018 , 169, 615-623	4.4	7
256	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018 , 124, 2299-2305	6.4	6
255	Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. <i>American Journal of Clinical Pathology</i> , 2018 , 149, 253-261	1.9	17
254	Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue. <i>Cancer</i> , 2018 , 124, 866	6.4	
253	Inflammatory breast cancer biology: the tumour microenvironment is key. <i>Nature Reviews Cancer</i> , 2018 , 18, 485-499	31.3	133
252	Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. <i>Human Pathology</i> , 2018 , 77, 121-129	3.7	17
251	The Emerging Impact of Social Media on Cancer Patient Education in Japan. <i>Oncologist</i> , 2018 , 23, e105-e106	10.6	
250	Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. <i>Clinical Breast Cancer</i> , 2018 , 18, e73-e77	3	21
249	BRCA mutations in women with inflammatory breast cancer. <i>Cancer</i> , 2018 , 124, 466-474	6.4	11
248	CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer. <i>Scientific Reports</i> , 2018 , 8, 9427	4.9	16
247	Survivorship and Advocacy in Inflammatory Breast Cancer. <i>Journal of Cancer</i> , 2018 , 9, 1430-1436	4.5	4
246	International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. <i>Journal of Cancer</i> , 2018 , 9, 1437-1447	4.5	45
245	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , 2018 , 18, e1283-e1288	3	8
244	Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. <i>Breast</i> , 2018 , 39, 148-149	3.6	2
243	Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. <i>PLoS ONE</i> , 2018 , 13, e0195932	3.7	5
242	Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole. <i>Therapeutic Advances in Medical Oncology</i> , 2018 , 10, 1758835918786858	5.4	358

241	Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 1207-1213	13.4	39
240	Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer. <i>Oncotarget</i> , 2018 , 9, 6872-6882	3.3	5
239	Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes. <i>Breast Cancer Research and Treatment</i> , 2018 , 171, 501-511	4.4	4
238	Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. <i>European Journal of Cancer</i> , 2018 , 89, 64-71	7.5	3
237	Survival Outcomes by Mutation Status in Metastatic Breast Cancer. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	23
236	ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2689-2701	6.1	36
235	Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. <i>PLoS ONE</i> , 2018 , 13, e0204372	3.7	8
234	Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype. <i>PLoS ONE</i> , 2018 , 13, e0204513	3.7	25
233	Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. <i>Journal of Cancer</i> , 2018 , 9, 3640-3646	4.5	13
232	Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. <i>Surgical Clinics of North America</i> , 2018 , 98, 787-800	4	29
231	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. <i>Clinical Biomechanics</i> , 2018 , 56, 61-69	2.2	5
230	Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy. <i>British Journal of Cancer</i> , 2017 , 116, 509-514	8.7	14
229	Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 463-479	5.9	29
228	Identification of frequent somatic mutations in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 263-272	4.4	20
227	Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. <i>Cancer</i> , 2017 , 123, 2422-2431	6.4	18
226	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 57-67	4.4	19
225	Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4780-4792	12.9	25
224	Novel therapeutic strategies in the treatment of triple-negative breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2017 , 9, 493-511	5.4	44

223	Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC). <i>Neoplasia</i> , 2017 , 19, 564-573	6.4	15
222	Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. <i>Lancet Oncology</i> , 2017 , 18, e228-e232	21.7	54
221	Androgen Receptor Function and Androgen Receptor-Targeted Therapies in Breast Cancer: A Review. <i>JAMA Oncology</i> , 2017 , 3, 1266-1273	13.4	109
220	Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer. <i>Cancer</i> , 2017 , 123, 2618-2625	6.4	8
219	Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''. <i>British Journal of Cancer</i> , 2017 , 116, e11	8.7	
218	Somatic mutations reveal asymmetric cellular dynamics in the early human embryo. <i>Nature</i> , 2017 , 543, 714-718	50.4	157
217	Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes. <i>Cancer Medicine</i> , 2017 , 6, 2515-2522	4.8	13
216	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017 , 8, 2004-2009	4.5	9
215	Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors. <i>PLoS ONE</i> , 2017 , 12, e0170081	3.7	2
214	Androgen receptor expression on circulating tumor cells in metastatic breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0185231	3.7	17
213	Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. <i>Journal of Cancer</i> , 2017 , 8, 1726-1732	4.5	3
212	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017 , 8, 1045-1052	4.5	7
211	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , 2017 , 8, 1009-1017	4.5	5
210	Thrombocytosis as a prognostic factor in inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 166, 819-832	4.4	11
209	Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2981-2988	3.1	19
208	Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. <i>Annals of Oncology</i> , 2017 , 28, 2420-2428	10.3	61
207	Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. <i>Breast Cancer Research</i> , 2017 , 19, 93	8.3	33
206	In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC. <i>Breast Cancer Research and Treatment</i> , 2017 , 165, 779-781	4.4	4

205	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2026-2032	4.5	18
204	Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10 Anniversary Conference. <i>Journal of Cancer</i> , 2017 , 8, 3607-3614	4.5	9
203	Immune and molecular determinants of response to neoadjuvant chemotherapy in inflammatory breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11501-11501	2.2	2
202	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 35656-35668	3.3	32
201	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 14897-14911	3.3	28
200	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 67904-67917	3.3	24
199	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017 , 8, 70481-70495	3.3	10
198	MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer. <i>Biochemical and Biophysical Research Communications</i> , 2017 , 489, 484-489	3.4	9
197	Non-glycanated Decorin Is a Drug Target on Human Adipose Stromal Cells. <i>Molecular Therapy - Oncolytics</i> , 2017 , 6, 1-9	6.4	16
196	Impact of clinical trial on survival outcomes. <i>Breast Cancer Research and Treatment</i> , 2016 , 159, 273-81	4.4	3
195	Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. <i>Carcinogenesis</i> , 2016 , 37, 1180-1189	4.6	19
194	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12780-12785	11.5	27
193	Epidemiological risk factors associated with inflammatory breast cancer subtypes. <i>Cancer Causes and Control</i> , 2016 , 27, 359-66	2.8	27
192	MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. <i>Modern Pathology</i> , 2016 , 29, 330-46	9.8	30
191	MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 95, 791-9	4	20
190	Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11532-11532	2.2	1
189	Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 559-559	2.2	1
188	Open-label phase Ib study of entinostat (E), and lapatinib (L) alone, and in combination with trastuzumab (T) in patients (pts) with HER2+ metastatic (mHER2+) breast cancer after progression on trastuzumab.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 609-609	2.2	3

187	Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. <i>Oncotarget</i> , 2016 , 7, 82482-82492	3.3	57
186	Clinical outcomes based on multigene profiling in metastatic breast cancer patients. <i>Oncotarget</i> , 2016 , 7, 76362-76373	3.3	18
185	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31
184	Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. <i>Oncotarget</i> , 2016 , 7, 28329-39	3.3	43
183	Inflammatory and Locally Advanced Breast Cancer 2016 , 411-435		
182	Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1087-1087	2.2	1
181	Effects of CDK4/6 Inhibition in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Cells with Acquired Resistance to Paclitaxel. <i>Journal of Cancer</i> , 2016 , 7, 947-56	4.5	9
180	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0152585	3.7	14
179	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016 , 21, 21-7	5.7	9
178	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	52
177	Neoadjuvant nab-paclitaxel in the treatment of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 427-440	4.4	16
176	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	10.4	1193
175	Impact of androgen receptor expression in fluoxymesterone-treated estrogen receptor-positive metastatic breast cancer refractory to contemporary hormonal therapy. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 101-109	4.4	9
174	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 2	8.3	33
173	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 458-66	3	9
172	Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. <i>Breast Cancer Research and Treatment</i> , 2015 , 152, 407-16	4.4	50
171	High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 91, 1072-80	4	28
170	Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. <i>Breast Cancer Research</i> , 2015 , 17, 42	8.3	42

169	Challenging a traditional paradigm: 12-year experience with autologous free flap breast reconstruction for inflammatory breast cancer. <i>Plastic and Reconstructive Surgery</i> , 2015 , 135, 262e-269e	2.7	18
168	Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2015 , 1, 1311-8	13.4	52
167	Circulating Tumor Cells and Recurrence After Primary Systemic Therapy in Stage III Inflammatory Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	21
166	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2773-81	6.1	51
165	Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. <i>American Journal of Clinical Pathology</i> , 2015 , 144, 713-21	1.9	26
164	Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2753-62	2.2	295
163	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2687-99	6.1	10
162	Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 495-508	4.4	40
161	Development of PEA-15 using a potent non-viral vector for therapeutic application in breast cancer. <i>Cancer Letters</i> , 2015 , 356, 374-381	9.9	10
160	Clinical characteristics and outcome of bone-only metastasis in inflammatory and noninflammatory breast cancers. <i>Clinical Breast Cancer</i> , 2015 , 15, 37-42	3	5
159	Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy. <i>Cancer</i> , 2015 , 121, 4324-32	6.4	22
158	Outcomes After Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015 , 38, 242-7	2.7	22
157	Comprehensive Two- and Three-Dimensional RNAi Screening Identifies PI3K Inhibition as a Complement to MEK Inhibitor AS703026 for Combination Treatment of Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 1306-19	4.5	14
156	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 310-8	4.5	14
155	Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. <i>Oncotarget</i> , 2015 , 6, 12890-908	3.3	80
154	Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. <i>Molecular Oncology</i> , 2015 , 9, 1155-68	7.9	111
153	Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0132710	3.7	69
152	Challenges and perspective of drug repurposing strategies in early phase clinical trials. <i>Oncoscience</i> , 2015 , 2, 576-80	0.8	29

151	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015 , 6, 2604-14	3.3	27
150	Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. <i>Clinical Breast Cancer</i> , 2014 , 14, e81-8	3	14
149	Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. <i>Stem Cells Translational Medicine</i> , 2014 , 3, 849-56	6.9	51
148	The role of inflammation in inflammatory breast cancer. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 816, 53-73	3.6	43
147	EZH2 expression correlates with locoregional recurrence after radiation in inflammatory breast cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014 , 33, 58	12.8	20
146	A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression. <i>Breast Cancer Research and Treatment</i> , 2014 , 146, 259-72	4.4	34
145	Predictors of durable no evidence of disease status in de novo metastatic inflammatory breast cancer patients treated with neoadjuvant chemotherapy and post-mastectomy radiation. <i>SpringerPlus</i> , 2014 , 3, 166		15
144	Expression of androgen receptor in inflammatory breast cancer and its clinical relevance. <i>Cancer</i> , 2014 , 120, 1775-9	6.4	6
143	Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. <i>Cell Reports</i> , 2014 , 7, 488-500	10.6	38
142	High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. <i>PLoS ONE</i> , 2014 , 9, e83113	3.7	65
141	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014 , 5, 745-53	4.5	32
140	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014 , 16, 440	8.3	77
139	Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2018-24	2.2	84
138	Primary tumor resection as a component of multimodality treatment may improve local control and survival in patients with stage IV inflammatory breast cancer. <i>Cancer</i> , 2014 , 120, 1319-28	6.4	45
137	Gene signature-guided dasatinib therapy in metastatic breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5265-71	12.9	20
136	Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. <i>Oncologist</i> , 2014 , 19, 909-14	5.7	13
135	(18)F-FDG PET/CT predicts survival in patients with inflammatory breast cancer undergoing neoadjuvant chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1809-16	8.8	16
134	TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase. <i>Cancer Research</i> , 2013 , 73, 6516-25	10.1	53

133	Latest biopsy approach for suspected metastases in patients with breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 711-9	19.4	17
132	Breast Cancer Biomarkers: Utility in Clinical Practice. <i>Current Breast Cancer Reports</i> , 2013 , 5, 284	0.8	15
131	A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations. <i>Clinical Breast Cancer</i> , 2013 , 13, 460-4	3	9
130	A prospective study of bone tumor response assessment in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2013 , 13, 24-30	3	28
129	Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. <i>Breast Cancer Research</i> , 2013 , 15, R112	8.3	39
128	Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 523-31	4.4	22
127	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. <i>Clinical Cancer Research</i> , 2013 , 19, 4685-96	12.9	99
126	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 761-72	4.4	41
125	Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 1099-111	6.1	15
124	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. <i>Clinical Cancer Research</i> , 2013 , 19, 5533-40	12.9	476
123	Paclitaxel and Trastuzumab as Maintenance Therapy in Patients with HER2-Positive Metastatic Breast Cancer Who Underwent High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , 2013 , 4, 679-85	4.5	4
122	Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. <i>Journal of Cancer</i> , 2013 , 4, 697-702	4.5	4
121	The antihelminthic drug pyrvinium pamoate targets aggressive breast cancer. <i>PLoS ONE</i> , 2013 , 8, e71508	3.7	32
120	A Brief Review of the Biophysical Hallmarks of Metastatic Cancer Cells 2013 , 1, 59-66		16
119	Breast cancer evaluation and targeted investigational therapy (BEAT-IT): A pilot prospective tissue testing to guide clinical trial selection.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 532-532	2.2	1
118	Bone Metastasis of Breast Cancer 2013 , 189-209		
117	Serum HER2 levels determined by two methods in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2012 , 17, 55-62	4.2	6
116	Inflammatory breast cancer: what we know and what we need to learn. <i>Oncologist</i> , 2012 , 17, 891-9	5.7	108

115	Role of epidermal growth factor receptor in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 136, 331-45	4.4	371
114	Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2012 , 12, 264-9	3	67
113	Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 1381-6	4	34
112	Microfluidics separation reveals the stem-cell-like deformability of tumor-initiating cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 18707-12	11.5	163
111	Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/ β -catenin signaling. <i>Stem Cells</i> , 2012 , 30, 2366-77	5.8	83
110	Bone Metastases 2012 , 591-609		2
109	Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases. <i>Cancer</i> , 2012 , 118, 2039-47	6.4	17
108	Improvement of survival and prospect of cure in patients with metastatic breast cancer. <i>Breast Cancer</i> , 2012 , 19, 191-9	3.4	53
107	Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. <i>International Journal of Clinical Oncology</i> , 2012 , 17, 96-104	4.2	72
106	Signaling Pathways in Inflammatory Breast Cancer 2012 , 151-160		
105	Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. <i>Journal of Clinical Oncology</i> , 2012 , 30, 729-34	2.2	174
104	Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2526-34	6.1	165
103	Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1239-41	1.9	16
102	Metastasis in the breast mimicking inflammatory breast cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, e202-6	2.2	4
101	Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. <i>Oncologist</i> , 2012 , 17, 233-8	5.7	17
100	MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 360-9	6.1	21
99	Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. <i>Journal of Clinical Oncology</i> , 2012 , 30, 593-9	2.2	295
98	Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Cancer</i> , 2012 , 3, 369-80	4.5	58

97 Systemic and Targeted Therapy **2012**, 85-99

96 Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study **2012**, 225-242

95 High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation in Inflammatory Breast Cancer **2012**, 127-138

94 Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. *Breast Cancer Research*, **2011**, 13, R67 8.3 161

93 Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt. *Journal of Cancer*, **2011**, 2, 435-42 4.5 16

92 Targeting EGFR in Triple Negative Breast Cancer. *Journal of Cancer*, **2011**, 2, 324-8 4.5 98

91 Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27. *Gynecologic Oncology*, **2011**, 122, 641-7 4.9 19

90 Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. *Breast Cancer Research and Treatment*, **2011**, 125, 785-95 4.4 54

89 Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series. *International Journal of Clinical Oncology*, **2011**, 16, 596-600 4.2 10

88 Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study. *Cancer*, **2011**, 117, 1819-26 6.4 102

87 Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. *Cancer*, **2011**, 117, 5476-84 6.4 56

86 Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. *International Journal of Cancer*, **2011**, 129, 417-23 7.5 81

85 Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer. *Oncologist*, **2011**, 16, 772-82 5.7 13

84 Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer. *Oncologist*, **2011**, 16, 956-657 8

83 A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. *JAMA - Journal of the American Medical Association*, **2011**, 305, 1873-81 27.4 414

82 High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. *Journal of Clinical Oncology*, **2011**, 29, 3214-23 2.2 72

81 Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. *Oncologist*, **2011**, 16, 1675-83 5.7 70

80 High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. *Journal of Clinical Oncology*, **2011**, 29, 3224-31 2.2 52

79	Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis. <i>Oncologist</i> , 2011 , 16, 155-64	5.7	53
78	FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. <i>Oncologist</i> , 2011 , 16, 1111-9	5.7	58
77	Information sharing and case conference among the multidisciplinary team improve patients' perceptions of care. <i>Open Nursing Journal</i> , 2011 , 5, 79-85	0.6	12
76	PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. <i>Clinical Cancer Research</i> , 2010 , 16, 1802-11	12.9	33
75	18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1213-8	8.9	51
74	Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser ³²⁷ phosphorylation in epidermal growth factor receptor-expressing breast cancer. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 3090-9	6.1	16
73	ABC conceptual model of effective multidisciplinary cancer care. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 544-7	19.4	13
72	Future directions of bone-targeted therapy for metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 641-51	19.4	85
71	Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. <i>Journal of Neuro-Oncology</i> , 2010 , 100, 449-57	4.8	14
70	Inflammatory breast cancer: the disease, the biology, the treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2010 , 60, 351-75	220.7	233
69	Targeted therapy in inflammatory breast cancer. <i>Cancer</i> , 2010 , 116, 2758-9	6.4	10
68	Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 889-95	4	35
67	Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. <i>Breast Journal</i> , 2010 , 16, 327-30	1.2	31
66	Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST. <i>Journal of Cancer</i> , 2010 , 1, 80-92	4.5	161
65	Lapatinib in the Treatment of Breast Cancer. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S52		
64	Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 6639-48	12.9	95
63	A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2375-82	6.1	29
62	Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. <i>International Journal of Hematology</i> , 2009 , 90, 627-634	2.3	2

61	Maintenance of HCT116 colon cancer cell line conforms to a stochastic model but not a cancer stem cell model. <i>Cancer Science</i> , 2009 , 100, 2275-82	6.9	39
60	Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3303-11	2.2	126
59	Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1465-74	4.7	30
58	Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer. <i>Clinical Breast Cancer</i> , 2009 , 9, 173-7	3	7
57	Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells. <i>Breast Cancer Research</i> , 2009 , 11, R12	8.3	55
56	Molecular targets for treatment of inflammatory breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 387-94	19.4	44
55	Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. <i>Lancet Oncology</i> , 2009 , 10, 606-14	21.7	120
54	Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. <i>Future Oncology</i> , 2009 , 5, 1585-603	3.6	45
53	Stem Cell Transplantation with 90yttrium Ibritumomab Tiuxetan(90YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.. <i>Blood</i> , 2009 , 114, 868-868	2.2	1
52	Autologous Stem Cell Mobilization with Cytokines and in-Vivo Alemtuzumab in Patients with T-Cell Non-Hodgkin's Lymphoma (T-NHL).. <i>Blood</i> , 2009 , 114, 3213-3213	2.2	
51	The medical treatment of inflammatory breast cancer. <i>Seminars in Oncology</i> , 2008 , 35, 64-71	5.5	27
50	PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival. <i>Cancer Research</i> , 2008 , 68, 9302-10	10.1	59
49	Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1846-50	6.1	62
48	Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. <i>Haematologica</i> , 2008 , 93, 257-64	6.6	117
47	Stem Cell Transplantation for Metastatic and High-Risk Nonmetastatic Breast Cancer: A Novel Treatment Approach 2008 , 387-410		
46	Gonadal failure after treatment of hematologic malignancies: from recognition to management for health-care providers. <i>Nature Clinical Practice Oncology</i> , 2008 , 5, 78-89		26
45	Leukemia-Associated Primary Granule Proteins (PGPs) Elastase-2 and Proteinase-3 Are Aberrantly Expressed in Solid Tumors: A Potential Therapeutic Target for PR1-Directed Immunotherapy. <i>Blood</i> , 2008 , 112, 5440-5440	2.2	0
44	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 34-42	3	115

43	Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. <i>Cancer</i> , 2007 , 110, 1436-44	6.4	153
42	Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. <i>Cancer Research</i> , 2007 , 67, 5779-88	10.1	102
41	Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 2168-77	6.1	55
40	Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 227-35	6.1	22
39	What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 31-3	4.7	12
38	Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 975-85	4.7	4
37	Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. <i>Breast Cancer Research</i> , 2007 , 9, R41	8.3	4
36	Zevalin /BEAM/Rituximab vs BEAM/Rituximab and Autologous Stem Cell Transplantation (ASCT) for Relapsed Chemosensitive Diffuse Large B-Cell Lymphoma (DLBCL): Impact of the IPI and PET Status.. <i>Blood</i> , 2007 , 110, 620-620	2.2	5
35	Trials and Tribulations in Developing Clinical Trials of Gene Therapy 2007 , 387-398		
34	Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies.. <i>Blood</i> , 2007 , 110, 48-48	2.2	
33	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 471-9	3	60
32	Prognostic value of nodal ratios in node-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2910-6	2.2	157
31	High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. <i>Bone Marrow Transplantation</i> , 2006 , 37, 929-35	4.4	4
30	Efficacy and Safety of Yttrium 90 (90Y) Ibritumomab Tiuxetan in Autologous and Nonmyeloablative Stem Cell Transplantation (NST) for Relapsed Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 315-315	2.2	11
29	Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model. <i>Cancer Research</i> , 2005 , 65, 8406-13	10.1	24
28	Cyclin A-associated kinase activity is needed for paclitaxel sensitivity. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 1039-46	6.1	19
27	Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation. <i>Haematologica</i> , 2005 , 90, 1725-6	6.6	15
26	Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. <i>Cancer Research</i> , 2004 , 64, 2502-8	10.1	223

25	Graft-versus-breast cancer effect by allogeneic hematopoietic stem-cell transplantation: a possible new frontier. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3846-7	2.2	2
24	Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. <i>Journal of Controlled Release</i> , 2004 , 97, 357-69	11.7	124
23	Bone imaging in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2942-53	2.2	441
22	The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 794-804	4.7	19
21	Immunotherapy with Donor Leukocyte Infusions (DLIS) in Relapsed Hodgkin's Disease (HD) Following Allogeneic Stem Cell Transplantation (ALLO-SCT): CD3+ Cell Dose, GVHD and Disease Response.. <i>Blood</i> , 2004 , 104, 1654-1654	2.2	1
20	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Patients Aged 65 Years or Older with AML and MDS.. <i>Blood</i> , 2004 , 104, 2301-2301	2.2	2
19	Targeted Radiotherapy to the Skeleton Using ¹⁶⁶ Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. <i>Blood</i> , 2004 , 104, 5239-5239	2.2	1
18	Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. <i>Blood</i> , 2003 , 102, 3829-36	2.2	125
17	Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 330-40	4.7	6
16	Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. <i>British Journal of Haematology</i> , 2002 , 119, 131-4	4.5	51
15	Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene. <i>Cancer Research</i> , 2002 , 62, 6712-6	10.1	41
14	Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. <i>Blood</i> , 2001 , 97, 631-7	2.2	508
13	E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy. <i>Breast Cancer</i> , 2001 , 8, 285-93	3.4	18
12	Fatal Salmonella group G enteritis mimicking intestinal graft-versus-host disease in a bone marrow transplant recipient. <i>Transplant Infectious Disease</i> , 2001 , 3, 29-33	2.7	4
11	Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. <i>Cancer</i> , 2001 , 92, 1775-82	6.4	63
10	Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2001 , 67, 227-33	7.1	18
9	Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. <i>Journal of Clinical Oncology</i> , 2001 , 19, 3422-33	2.2	182
8	Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. <i>British Journal of Haematology</i> , 2000 , 111, 18-29	4.5	1

7	High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. <i>Clinical Breast Cancer</i> , 2000 , 1, 197-209; discussion 210	3	6
6	Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy. <i>Hematology/Oncology Clinics of North America</i> , 1999 , 13, 1041-57, vii-viii	3.1	38
5	Primary malignant teratoma of the thyroid gland: report and discussion of two cases. <i>Head and Neck</i> , 1998 , 20, 649-53	4.2	13
4	Primary malignant teratoma of the thyroid gland: Report and discussion of two cases 1998 , 20, 649		2
3	Chemosensitization of HER-2/neu-overexpressing human breast cancer cells to paclitaxel (Taxol) by adenovirus type 5 E1A. <i>Oncogene</i> , 1997 , 15, 953-60	9.2	82
2	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 40, 321-9	3.5	203
1	Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance		2